The Institutes for Pharmaceutical Discovery

The Institutes for Pharmaceutical Discovery, LLC (IPD) is a privately held company founded by James M. Nolan, President and CEO, and Gordon Polley, Chairman.

IPD is managed by a cadre of experienced pharmaceutical executives, financial managers and dedicated senior scientists, all of whom have had extensive experience in pharmaceutical and life science industries. This group also oversees the vision and function of each individual institute it creates...

The Institute for Drug Discovery, L.L.C. (IDD), an affiliate of The Institutes for Pharmaceutical Discovery, L.L.C., is a Branford CT-based pharmaceutical research company. IDD builds on selected biological discoveries byUniversityresearchers as well as its own scientists and creates early pipeline assets appropriate for partnering with pharmaceutical companies. To accomplish this, IDD optimizes screening assays, designs and synthesizes novel compounds, tests candidates in in vitro drug metabolism studies and in vivo pharmacokinetic testing, and demonstrates a proof of efficacy in disease models in vivo. The ultimate aim of these studies is to develop small molecule compounds suitable for licensing.

Our second institute, The Institute for Bioanalytics, LLC, (IBA), founded in 1997, provides services for pharmaceutical and diagnostic clients. IBA's services include the development and validation of in vitro assays for high throughput screening, measuring the physiological effects of a particular agent, or helping identify the appropriate patients for a given therapy through pharmacogenomic approaches. The development of therapy-specific bioanalytical assays will enable physicians to target patients more successfully for new therapeutical agents, thereby increasing efficacy, minimizing the likelihood of deleterious side effects and/or enhancing overall safety.